Antisense oligonucleotides for cancer therapy—an overview
- 1 August 2003
- journal article
- review article
- Published by Elsevier in Lung Cancer
- Vol. 41, 81-88
- https://doi.org/10.1016/s0169-5002(03)00147-8
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Antisense therapy for cancer—the time of truthThe Lancet Oncology, 2002
- Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2000
- Potent and nontoxic antisense oligonucleotides containing locked nucleic acidsProceedings of the National Academy of Sciences, 2000
- Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structureJournal of Molecular Biology, 1999
- Tetranucleotide GGGA Motif in Primary RNA TranscriptsPublished by Elsevier ,1998
- Molecular Mechanisms of Antisense Drugs: RNase HAntisense and Nucleic Acid Drug Development, 1998
- Selecting effective antisense reagents on combinatorial oligonucleotide arraysNature Biotechnology, 1997
- Ein neuer Zugang zu 2′‐O‐Alkylribonucleosiden und Eigenschaften deren OligonucleotideHelvetica Chimica Acta, 1995
- Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.Proceedings of the National Academy of Sciences, 1978
- Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation.Proceedings of the National Academy of Sciences, 1977